Clinical Trials

1,200 enrolled

Metastatic Castration-Resistant Prostate Cancer

NCT03917381 2026-02-11

GEN1046 Safety Trial in Patients With Malignant Solid Tumors

429 enrolled

Solid Tumors

NCT04577014 2026-02-11

Retifanlimab (Anti-PD-1 Antibody) With Gemcitabine and Docetaxel in Patients With Advanced Soft Tissue Sarcoma

98 enrolled

Sarcoma

NCT03598595 2026-02-04

Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma

31 enrolled

Sarcoma

Osteosarcoma

NCT05616624 2026-02-04

ADI-PEG 20 in Combination With Gemcitabine and Docetaxel After Progression on Frontline Therapy in Non-small Cell and Small Cell Lung Cancers

31 enrolled

Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

NCT05094336 2026-01-30

MTAPESTRY 101

CNSGastrointestinalHead & NeckThoracic

329 enrolled

Squamous Cell Carcinoma of Head and Neck, Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Glioma, Stomach Neoplasms

NCT05867420 2026-01-27

A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.

594 enrolled

Advanced Solid Tumors

NCT04633252 2026-01-16

M9241 in Combination With Docetaxel in Adults With Metastatic Castration Sensitive and Castration Resistant Prostate Cancer

86 enrolled

Prostatic Neoplasms

NCT06879717 2026-01-16

PULMO-01

45 enrolled

Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

NCT06741644 2026-01-09

A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors

660 enrolled

Advanced Solid Tumors

NCT06568094 2025-12-31

A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer

100 enrolled

Prostatic Neoplasms

NCT05256745 2025-12-24

RAGE

48 enrolled

Cancer Related Cognitive Decline

NCT03337698 2025-12-12

Morpheus Lung

314 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05664971 2025-12-02

JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer

119 enrolled

Advanced Lung Cancer

NCT05516914 2025-11-28

A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors

490 enrolled

Tumor-Agnostic

Neoplasms

NCT05383482 2025-11-17

Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1

GastrointestinalGynecologic

22 enrolled

Uterine Cervical Neoplasms, Esophageal Neoplasms, Endometrial Neoplasms

NCT06615752 2025-11-12

Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients

99 enrolled

Prostatic Neoplasms

NCT06228326 2025-10-24

KYANITE-1

250 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT06682780 2025-09-25

A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours

320 enrolled

Advanced Solid Tumor

NCT05381038 2025-09-23

Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI

10 enrolled

BreastGastrointestinal

Breast Neoplasms, Gastrointestinal Neoplasms, Neoplasms

NCT06531434 2025-09-22

Establishing Best Treatment Strategy for T4 Esophageal Cancer

22 enrolled

Esophageal Cancer TNM Staging Primary Tumor (T) T4

NCT06704191 2025-09-22

In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial

40 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT07070440 2025-08-29

DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)

100 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06732856 2025-07-28

NEO-CLAUD

57 enrolled

Stomach Neoplasms

NCT04381832 2025-07-22

Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

173 enrolled

Prostatic Neoplasms, Castration-Resistant

NCT05714553 2025-07-18

NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

19 enrolled

Squamous Cell Carcinoma of Head and Neck, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Esophageal Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT02039336 2025-07-08

M13DAP

35 enrolled

Colorectal Neoplasms

NCT05910827 2025-06-22

Study of an Anti-HER3 Antibody, HMBD-001, With Docetaxel +/- Cetuximab in Advanced Squamous Non-small Cell Lung Cancers, and HMBD-001 + Cetuximab in Advanced Squamous Cell Cancers

98 enrolled

Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung

NCT04947189 2025-05-15

4CAST

65 enrolled

Triple Negative Breast Neoplasms

NCT05319873 2025-05-13

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

18 enrolled

Anatomic Stage II Breast Cancer AJCC v8

NCT06480110 2025-04-13

Ebastine in Combination With Docetaxel as a Treatment for Castration-resistant Metastatic Prostate Cancer

30 enrolled

Metastatic Castration-resistant Prostate Cancer

NCT04256707 2025-03-19

SPRINT

126 enrolled

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT05543629 2025-03-18

A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer

36 enrolled 26 charts

Carcinoma, Non-Small-Cell Lung

NCT05062980 2025-02-20

Acclaim-2

5 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05431270 2025-01-31

Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 MAb, Administered Alone and in Combination with a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)

40 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

NCT03317158 2025-01-30

ADAPT-BLADDER

55 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06732531 2025-01-09

Safety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder Cancer

48 enrolled

Urinary Bladder Neoplasms

NCT04276493 2024-12-06

Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab

71 enrolled

BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms

NCT02229084 2024-11-07

Vaccination of High Risk Breast Cancer Patients

58 enrolled 27 charts

Breast Neoplasms

NCT03693612 2024-08-28

GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors

DermatologicGenitourinaryHead & NeckThoracic

26 enrolled 47 charts

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasms

NCT05816499 2024-06-17

AK104IIT018

50 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03095612 2024-06-13

Phase 1/2 Trial of Selinexor (KPT-330) With Docetaxel for Non-small Cell Lung Cancer (NSCLC)

41 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung

NCT02735239 2024-03-22

Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer

73 enrolled 18 charts

Adenocarcinoma Of Esophagus, Diabetes Mellitus, Insulin-Dependent, 12, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms

NCT02718820 2024-01-09

Pembrolizumab Plus Docetaxel for the Treatment of Recurrent or Metastatic Head and Neck Cancer